Wuhan Desheng Biochemical Technology Co., Ltd

In biochemical and molecular biology experiments, the selection of buffering agents directly affects the accuracy and stability of experimental results. BICINE buffer, as a commonly used zwitterionic buffer, plays an important role in numerous experimental scenarios due to its excellent buffering ability within a specific pH range. However, its insolubility in organic solvents such as acetone, DMAc, DMSO, DMF, etc. has brought special experimental challenges to researchers and prompted them to think more deeply about the scientific logic of buffer selection. BICINE's insolubility to organic solvents is particularly prominent in organic phase experimental systems. In experiments such as drug synthesis and organic reaction catalysis that require the participation of organic solvents, the solubility of buffering agents directly determines the uniformity of the reaction system. When organic solvents such as acetone are present in the experimental system, BICINE will form suspended particles due to its inability to dissolve, which not only destroys the stability of the system, but may also interfere with the reaction process, resulting in distorted experimental data. In this case, researchers often need to redesign the experimental plan, either by changing the solvent system or finding alternative buffering agents, which undoubtedly increases the complexity and cost of the experiment. For experiments that rely on organic solvents for substance extraction or purification, the impact of BICINE's insolubility is more significant. In the process of protein purification, certain steps require the use of organic solvents such as DMSO to maintain protein conformation. If BICINE is used as a buffer at this time, undissolved particles may adsorb the target protein, causing sample loss; In organic chromatography analysis, insoluble substances in buffering agents may also clog the chromatography column, affecting the service life and detection accuracy of the instrument. These practical issues require researchers to carefully evaluate the applicability of BICINE when facing organic phase experiments. Despite the aforementioned limitations, BICINE's outstanding performance in aqueous environments still makes it an important choice in the field of scientific research. In biological experiments under physiological conditions, BICINE can effectively maintain the pH stability of the system and has little effect on the activity of biomolecules, making it very suitable for experimental scenarios such as enzyme reactions and cell culture. Its good water solubility and chemical stability also make it widely used in clinical testing, biopharmaceuticals, and other fields. This characteristic also provides important insights for researchers in buffer selection: there is no "universal buffer" that is applicable to all scenarios, and experimental design must adhere to specific problem specific analysis. When selecting buffering agents, it is necessary to comprehensively consider factors such as the solvent type, pH range, temperature conditions, and compatibility with other reagents of the experimental system. When experiments involve organic solvents, buffering agents such as HEPES and MOPS that have better compatibility with organic solvents can be considered; In pure water systems, BICINE remains a highly cost-effective choice. The progress of scientific research often comes with a deeper understanding and flexible application of the characteristics of experimental materials. The solubility characteristics of BICINE buffer remind us that the "limitations" of experimental materials are precisely the "starting point" of scientific design. By fully understanding the advantages and disadvantages of each buffering agent, researchers can make optimal choices in complex experimental systems and provide solid guarantees for the reliability of scientific research results. As a professional manufacturer of BICINE, Desheng has established a comprehensive quality control system and strictly controls every production process to ensure that the product quality meets the requirements. And we have a professional sales and technical team that can quickly respond to customer needs and issues, providing timely and professional services to customers. If you have any needs, please feel free to contact us at any time!  

Phosphate cellulose column chromatography, as one of the core technologies in the field of biological molecule separation and purification, plays an important role in the preparation of biomolecules such as proteins and nucleic acids due to its efficient adsorption and separation performance. The core principle of this technology is to utilize the specific binding between the phosphate groups on the surface of phosphate cellulose medium and biomolecules, such as electrostatic interactions and hydrogen bonding, to achieve precise separation of target molecules. In this process, the selection and optimization of buffer directly affect the chromatography effect, and MES buffer, due to its unique physicochemical properties, has become the ideal choice for balancing and elution steps in this technology. The primary application of MES buffer (2-morpholine ethanesulfonic acid buffer) in phosphocellulose column chromatography is as an equilibrium solution, providing a stable initial environment for the chromatography system. Before starting the chromatography operation, a large amount of equilibrium solution needs to flow through the chromatography column to achieve thermodynamic equilibrium between the stationary phase (cellulose phosphate medium) and the mobile phase (MES buffer). The phosphate groups on the surface of the phosphate cellulose medium will dissociate under specific pH conditions, and the pH buffering range of MES buffer solution precisely matches the optimal working pH range of phosphate cellulose, which can accurately maintain the stability of the surface charge state of the medium. This stability ensures that the column is in a uniform initial state before sample loading, effectively avoiding differences in adsorption efficiency caused by local pH fluctuations, and laying the foundation for the repeatability and stability of subsequent separation. At the same time, the extremely low UV absorption characteristics of MES buffer also reduce interference with target molecule detection. During the elution stage, MES buffer achieves gradient separation of biomolecules by precisely regulating ion strength and pH value. The binding strength between biomolecules and phosphate cellulose medium depends on the electrostatic attraction between the surface charge of the molecule and the phosphate groups in the medium, which can be adjusted by changing the ionic strength of the buffer solution. In experiments, a mixed system of MES buffer and sodium chloride is usually used. By gradually increasing the concentration of sodium chloride (i.e. increasing the ionic strength), the ions in the solution compete with biomolecules to bind to the charged sites on the surface of phosphocellulose, thereby weakening the interaction between biomolecules and the medium. Due to the differences in the charged properties and molecular weight of different biomolecules, their binding strength with the medium varies. Therefore, they will be eluted successively in MES buffer solutions with different ionic strengths to achieve separation and purification. In addition, MES buffer has high chemical stability and is not easily reacted with biomolecules during chromatography, which can effectively maintain the natural structure and activity of biomolecules. This is crucial for subsequent functional research or applications. Meanwhile, its good solubility and low osmotic pressure also reduce damage to the chromatography column and potential impact on biomolecules. In summary, MES buffer plays an irreplaceable key role in phosphocellulose column chromatography technology by serving as an equilibrium solution to ensure the initial stability of the chromatography system and as an eluent to achieve precise separation of biomolecules through ion strength regulation. It provides an efficient and reliable solution for the separation and purification of biomolecules. As an advantageous manufacturer of MES buffer, Desheng, with its professional R&D team, advanced production technology, and strict quality control system, can stably supply high-quality MES buffer products with high purity, good stability, and excellent biocompatibility, which can meet the needs of biochemical experiments in different fields. If you have any relevant intentions, please click on the website to inquire about details and purchase!  

In the golden September, Yangcheng gathers. From September 26th to 29th, 2025, the global healthcare industry will once again focus on Guangzhou, welcoming the grand opening of the 92nd China International Medical Equipment Fair (CMEF). As an innovative force in the field of core raw materials for in vitro diagnostics (IVD), Hubei Xindesheng Materials Technology Co., Ltd. is ready to go. Led by the company's general manager, an elite team consisting of technical elites and domestic and foreign sales backbones set off from Hubei on September 25th to attend this top-level industry event (booth number: C06 in Hall 20.1), aiming to present a precise diagnostic technology feast to global customers with a series of innovative enzyme preparations and mature core products. 1, Innovation engine: New enzyme preparations make a heavyweight debut, empowering precise diagnosis in new dimensions At this year's CMEF, Xindesheng will launch a new generation of high-purity and highly stable enzyme preparation series that it has carefully developed, including key indicator detection materials such as lactate dehydrogenase (LDH), uricase (UO), creatine kinase isoenzyme (CK-MB), etc. These new products are not only a concentrated reflection of the company's research and development capabilities, but also directly address the higher demand for detection sensitivity, specificity, and inter batch stability in the current IVD testing market. These new enzyme preparations have injected strong power into Xindesheng's "innovation engine", indicating that the company has taken a more solid step on the road of independent research and development of key raw materials, aiming to help downstream reagent manufacturers enhance their product core competitiveness. 2, Stable cornerstone: Core product matrix appears together, showcasing the full chain supply strength While showcasing its innovative edge, Xindesheng will also showcase its traditional core product matrix that has been validated in the market for a long time, demonstrating its comprehensive strength as a reliable supplier. Biological buffering agents, such as Tris, HEPES, Bicine, etc., have excellent purity and provide a stable reaction environment for diagnostic reagents. Chemiluminescent reagents, including luminol and acridine ester luminescent reagents, have the advantages of high luminescence efficiency and sensitive reaction. Chromogenic substrates such as TOOS, TOPS, MAOS, MADB, etc. are sensitive and stable for color development, and are suitable for various enzyme immunoassay analyses. Blood collection tube additives: a full range of products including serum separation gel, anticoagulant, coagulant, silicification agent, etc., provide support for front-end sample processing. New Desheng's product line covers multiple key aspects of IVD reagent development and production, including reaction environment construction, signal generation, and sample preprocessing, demonstrating its strong ability to provide customers with a "one-stop" raw material solution. 3, Face to face communication: Elite teams gather to discuss new chapters of cooperation In this exhibition, Xindesheng not only sent out products, but also a powerful "think tank" and "service team". The general manager, technical experts, and domestic and foreign sales elites gather together to have zero distance and in-depth communication with customers and partners from around the world. Whether it's exploring cutting-edge technology trends, analyzing specific project requirements, or negotiating customized services and international market cooperation, the New Desheng team is fully prepared and looks forward to colliding ideas and listening to market voices on the open platform of CMEF. With more flexible and thoughtful services, we will explore the infinite possibilities of diagnostic technology development together with industry colleagues. Conclusion: At the right time for the grand event, Xindesheng is waiting for your visit in Guangzhou! The exhibition has now grandly opened, and excitement is unfolding! The booth of Hubei Xindesheng is ready, and our team is eagerly awaiting the visit of all new and old friends in Guangzhou with full enthusiasm. Now, by visiting the New Desheng booth (booth number: C06, Hall 20.1), you will be able to: Personally observe and understand the appearance and excellent performance of new enzyme preparations and core products; Face to face with the general manager and technical experts to deeply discuss your customized needs and technical challenges; Obtain the latest product information and cooperation policies. The opportunity is rare, and the grand event is in full swing! We look forward to meeting you in Yangcheng, seeking common development and a win-win future!

On September 19, 2025, the golden autumn brings a refreshing feeling and the fragrance of osmanthus flowers fills the air. In this beautiful season of harvest and hope, we warmly welcome our important strategic partner from afar - Ms. Anu Moturi, founder of Kriya Medical Technologies (KriyaMed), an Indian blood collection industry enterprise. This visit is a deep interaction between the two sides after embarking on a journey of cooperation, aimed at reviewing the fruitful cooperation process and jointly drawing up a grand blueprint for future development. During the visit, both parties held talks on the in-depth cooperation and future market strategy of EDTA K3 and separation gel, and conducted on-site inspections of our new Huanggang factory. Both sides walked together, sharing their cooperative friendship and seeking common development plans, creating a warm and harmonious atmosphere on site. Under the leadership of founder Anu Moturi, KriyaMed has become an undeniable force in the Indian blood collection tube market. Since establishing a partnership with our company 6-7 years ago, both parties have supported each other and grown together. Ms. Anu Moturi's personal visit this time not only reflects her appreciation for the long-term cooperative relationship with our company, but also demonstrates her firm determination to further deepen cooperation and jointly explore the market. At the beginning of the visit, our company's Chairman Mr. Wang Zhongxi, General Manager Ms. Wang Anqi and other senior leaders expressed their warmest welcome to Ms. Anu Moturi's visit. During the cordial and friendly talks, both sides jointly reviewed the achievements of their cooperation over the past five years. Ms. Anu Moturi expressed her sincere gratitude to our company for providing stable and high-quality product supply, as well as timely and professional technical services. She clearly stated that one of the core objectives of this visit is to explore with our company a more competitive cooperation price for EDTA K3 anticoagulant and core raw material separation gel based on a larger procurement scale in the future, in order to further enhance the competitiveness of KriyaMed products in the Indian market. More notably, Ms. Anu Moturi confidently shared KriyaMed's next strategic development plan. She announced that the company has set clear goals to significantly increase the production capacity and market share of separation gel blood collection tubes, striving to become the leader in the Indian separation gel blood collection tube market. To achieve this ambitious goal, KriyaMed plans to increase its procurement of separation gel from our company on one hand, and on the other hand, invest heavily to enhance its own production capacity. She emphasized that establishing a deeper strategic alliance with our company, a source enterprise with strong technology and production capacity guarantee, is the core cornerstone to achieve this goal. In order to enable our esteemed partners to fully understand our strength and commitment, Mr. Wang Zhongxi, Chairman, and Ms. Wang Anqi, General Manager, personally accompanied Ms. Anu Moturi to visit and inspect our new factory located in Huanggang. On this trip, she not only saw the strong existing production capacity of your company, but also saw the huge development potential for the future. She highly appreciates our company's continuous investment in production capacity and technological upgrades, believing that this provides a solid and reliable guarantee for its future large-scale procurement needs, and is full of confidence in the stability and growth of our long-term cooperation. The successful visit of Ms. Anu Moturi marks a new and deeper stage in our partnership with KriyaMed after five years of testing. From stable suppliers to strategic partners working together, this transformation is based on deep mutual trust and a shared vision. We firmly believe that with Ms. Anu Moturi's outstanding leadership and clear market strategy, the strong alliance between the two parties will bear even more fruitful results. Hubei Xindesheng will spare no effort to support Kriya Medical Technologies in achieving its grand goal of becoming a market leader in India with competitive prices, stable product quality, and a reliable supply chain, and jointly create a mutually beneficial and win-win future!